When it comes to managing chronic conditions and rare disease, the cost of treatment can be astronomical.
When it comes to managing chronic conditions and rare disease, the cost of treatment can be astronomical. Fran Gregory, PharmD, MBA, director of specialty pharmacy, Humana Pharmacy Solutions, offered her solutions to PBMI attendees, saying there are a variety of options to manage the rising costs of specialty drugs. Dr Gregory suggested that savings opportunities for providers, payers, and patients must include considerations such as utilization management, cost-effective delivery channels, and increasing adherence among members.
Dr Gregory says that utilization and inflation are related. Because there is a small population afflicted with chronic illness and rare disease, the cost to produce these prescription drugs is spread out among a smaller amount of patients. As inflation increases, so does the cost. For instance, one multiple sclerosis drug cost about $1500 in 2007. Today that same drug costs $4600.
She went on to describe that when managing conditions like chronic myeloid leukemia (CML), adherence greater than 90% was more than often a result of major molecular response or complete molecular response system requirements. She said strong adherence ensures that the prices of costlier specialty drugs do not go wasted—providers want to make sure that patients are taking medications as prescribed to order to improve outcomes.
To drive this level of adherence (>90 %) requires a system of alignment. The pharmacy benefit must align with the specialty pharmacy, and both must align with the medical benefit. Dr Gregory says aligning pharmacy and medical policy is important to lowering costs not only in specialty drugs but on high-priced assessments such as pharmacogenomic tests.
Other conditions such as rheumatoid arthritis and hepatitis C also require the development of better clinical management programs to control costs and drive adherence. A better management program would let patients know what to expect. In hepatitis C, for example, as more drug classes are developed, more leverage and options for managing the condition are provided. Dr Gregory says challenges lie ahead, but “We are gaining coverage in this space.”
Overall, she says, there is a 3-stage approach to making specialty drugs affordable: aligning the strategic management of medical, pharmacy, and special pharmacy.
Stephanie Holliday, PharmD, senior director of clinical operations for AcariaHealth, who co-presented with Dr Gregory, said there are trending outcomes in the management of MS with the newly approved oral agent, Tecfidera. AcariaHealth’s care management program utilizes such treatments to produce outcomes that provide cost savings. Underscoring Dr Gregory’s focus on medication adherence, she suggests that collaboration through patient portals and Web-based tools like AricaConnect is vital.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More